WCWei Chen

Wei Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wei Chen has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ki67 proliferation indices in advanced jejunoileal well‐differentiated neuroendocrine tumours are most prognostic when evaluated in mesenteric tumour deposits

    by Monika Vyas, Wei Chen, Raul S Gonzalez

    Background: Ki67 proliferation indices are used for grading well‐differentiated neuroendocrine tumours (NETs). Selection of tissue for staining can be challenging, especially in jejunoileal NETs (JI‐NETs), which can be multifocal and produce multiple metastases. This study aimed to determine parameters for selecting the most prognostically appropriate tissue for Ki67 staining in JI‐NETs. Materials and Methods: We identified JI‐NETs with at least one nodal metastasis and/or mesenteric tumour deposit. For each, we recorded patient age and sex; size of largest primary tumour, nodal metastasis and/or deposit; AJCC staging; and patient outcome (recurrence and disease‐specific death). We stained the largest primary, node and deposit in each case for Ki67 (clone SP6, Biocare Medical CRM325, 1:50) and also assessed mitotic rates. We photographed hotspot areas on each Ki67 slide. Ki67 index was calculated for each photo using QuPath digital image analysis software after training using a random forest supervised classifier. Twenty cases underwent manual Ki67 counting to validate QuPath results. All variables were compared to patient outcomes using standard univariate and multivariate Cox proportional hazard regression ( α = 0.05). Results: Among 75 JI‐NETs from 42 female and 33 male patients (mean age 61 years), 71 had positive nodes and 47 had deposits. Mean sizes of the largest primary tumours, nodal metastases and deposits were 1.97, 1.28 and 2.0 cm. Mean Ki67 was 1.82 (largest primaries), 2.24 (largest nodes) and 2.08 (largest deposits). In 51 cases (68%), the Ki67 of a node or deposit was higher than the primary tumour. Twenty‐one tumours (28%) recurred, with median projected time to recurrence time of 108 months. Over a median overall follow‐up of 72 months, six patients (8%) died of disease. Tumour deposit Ki67 was the only factor associated with increased risk of progression on multivariate analysis (hazard ratio [HR] 1.22 for each 1.0% increase, 95% confidence interval [CI] 1.02–1.46, P = 0.032); primary and nodal Ki67 were not, nor was the highest Ki67 or the Ki67 of the largest focus within each case. No Ki67 indices were significantly relevant to overall survival on multivariate analysis, though largest tumour deposit size was (HR 1.51 for each 1.0 cm increase, 95% CI 1.08–2.11, P = 0.015). Conclusions: Tumour deposits appear to play a key role in the outcome of patients with JI‐NETs. For meaningful Ki67 evaluation of JI‐NETs, the largest tumour deposit should be stained, if available.

  • A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study

    by Cecilia G Ethun, Colin M Court, Joanne F Chou, Lauren E Schleimer, Sarah McIntyre, Henry Walch, Jeremy Sharib, Sabran Masoud, Wei Chen, Victoria Aveson, et al.

    Background: Small bowel adenocarcinoma (SBA) is a rare malignancy with poor prognosis. Its clinical and pathologic characteristics are sparse, and few studies have examined its genetic features within the continuum of the gastrointestinal tract. Methods: Patients (n = 243) from six institutions with SBA and available tumor tissue underwent targeted tumor sequencing. A hidden genome classifier (HGC) was developed based on analyses of 286 gastroesophageal (foregut) and 286 colorectal (hindgut) cancers. SBA samples were assigned to foregut (n = 61), hindgut (n = 61) or mixed-type (n = 121) lineages using predefined HGC score thresholds. Overall survival (OS) was calculated from 90 days post resection until date of last follow-up for patients who underwent curative-intent resection. Results: HGC classified 54% of duodenal and 64% of intestinal-type periampullary tumors as foregut; 56% of jejunal and 68% of ileal tumors were classified as hindgut. Foregut showed amplifications in CDK12, CD3, EGFR, KRAS and cytoband changes at 8p21.1/15q26.3; hindgut harbored APC and KRAS mutations; mixed-type combined features. Median OS was 73 months (95%CI, 53 to 130) after curative-intent resection. The HGC prediction group (hindgut vs mixed-type, HR 2.80, 95%CI, 1.35-5.75) and age (HR 1.03, 95%CI, 1.01-1.05) were associated with decreased survival. Anatomic site was not associated with OS, whereas driver mutations ARID1A, KRAS and TP53 were associated with OS on univariate analysis. Conclusion: SBAs display genomic heterogeneity. The novel HGC stratifies these tumors based on homology to foregut or hindgut alterations and may be superior to anatomic location for characterizing pathology. Additional studies are needed to validate and further explore these findings.

  • Open Access

    Perplexing Severe Cholestasis in the Postpartum Period

    by Sarah Yosief, Wei Chen, Kimberly Wescoe, M.S. Branch, Mustafa Bashir, Kara Wegermann

    A 36-year-old postpartum woman with prior intrahepatic cholestasis of pregnancy and gallstone pancreatitis presented with right upper quadrant pain, jaundice, and elevated liver enzymes. Initial workup suggested drug-induced liver injury, but laboratory results worsened after antibiotics were discontinued. Imaging and liver biopsies revealed cholestasis and progressive fibrosis. Endoscopic retrograde cholangiopancreatography finally confirmed primary sclerosing cholangitis, though overlap with pregnancy-related liver conditions delayed diagnosis. This case highlights the diagnostic challenges of postpartum cholestasis and illustrates how primary sclerosing cholangitis may emerge in temporal association with pregnancy despite initially nondiagnostic imaging and histology.

  • Margin clearance and post‐procedure ablation decrease recurrence risk in endoscopic mucosal resections for Barrett's‐related neoplasia

    by Phoenix D Bell, Vivek Kaul, Krystle M Bittner, Irene Y Chen, Aaron R Huber, Olivia A Sagan, Wei Chen, Ilke Nalbantoglu, Raul S Gonzalez

    Aims: Endoscopic mucosal resection (EMR) is widely used for treating Barrett's‐related oesophageal dysplasia and low‐stage carcinoma. Disease can recur after this procedure. We analysed a large cohort of EMR specimens to assess clinical and histopathologic factors and their relationship to recurrence. Methods and results: We conducted a retrospective study of 129 patients who had in total 290 oesophageal EMRs for glandular neoplasia. Patient age, patient sex, specimen fragmentation, intestinal metaplasia, highest‐grade lesion, margin status and clearance, cancer invasion depth, lymphovascular invasion, tumour budding (using published guidelines for colorectal carcinoma), post‐procedure cryoablation/radiofrequency ablation and disease recurrence were recorded. Statistical analyses were performed on 227 eligible cases to determine the significance of these factors in local disease recurrence. Adenocarcinoma was the highest‐grade lesion in 42% of the 290 specimens, high‐grade dysplasia in 36% and low‐grade dysplasia in 22%. Mean age at first EMR was 66 years. Among the 227 statistically analysed cases, post‐procedure ablation was performed for 111 (49%) and recurrence of same or worse disease was documented in 104 (46%). Tumour depth and budding did not affect recurrence risk. On multivariate analysis, lack of post‐procedure ablation was associated with increased recurrence risk for high‐grade dysplasia and carcinoma. Additionally, poor differentiation and margin status were associated with increased recurrence risk for specimens with carcinoma. These relationships mostly held true for recurrence of same/worse neoplasia or recurrence of any neoplasia. Conclusions: Differentiation, margin status and post‐EMR ablation influence the risk of local disease recurrence for Barrett's‐related adenocarcinoma, while other factors such as tumour budding and lesional depth do not.


  • Diffuse expression of p16 in pancreatic neuroendocrine tumors (PanNETs) and the association of morphology variants

    by John Yablonski, Chanjuan Shi, Wei Chen

    Objective: Distinguishing grade 3 pancreatic neuroendocrine tumors (PanNETs) from neuroendocrine carcinomas (PanNECs) is sometimes challenging. Recently, a diffuse p16-positive pattern was reported in PanNECs but not in grade 3 PanNETs, suggesting that p16 could help differentiate these entities. This study aimed to investigate p16 expression in PanNETs of various grades and its association with clinicopathologic features. Methods: A total of 114 PanNETs were selected, and their H&E resection slides were reviewed for pathologic features, with a focus on morphologic variants. Tissue microarrays were constructed, and p16 immunohistochemistry was performed. The results were categorized as diffuse positive, partial positive, or negative. Patient electronic health records were reviewed for follow-up data. Results: Among the 114 PanNETs reviewed, 13 (11.4%) exhibited diffuse p16 expression, 40 (35.1%) were negative, and 61 (53.5%) had partial expression. Diffuse p16 expression occurred in 6 of 38 (15.8%) grade 1, 6 of 60 (10.0%) grade 2, and 1 of 16 (6.3%) grade 3 tumors. Expression did not differ substantially with patient demographics, tumor size, grading, staging, or survival, but diffuse p16 expression was more frequent in body/tail tumors (12/65 [18.5%], P = .019) and in stromal-rich tumors (10/23 [43.5%], P < .001). Conclusions: Diffuse p16 expression is not uncommon in PanNETs and may be associated with stroma-rich variants.


  • Vascular flow alteration is a dominant pattern of liver pathology in patients with orthotopic lung transplants: a retrospective observational study

    by Kasey J. McCollum, Bethany Freeland LeClair, Wei Chen, Chanjuan Shi, Kara Wegermann, Avani A. Pendse

    Aims: The number of orthotopic lung transplants (OLT) has skyrocketed since the 1960s, generating an ever‐increasing cohort of post‐OLT patients. Many challenges exist in the post‐OLT timeframe, including donor graft dysfunction, infection, malignancy, and immunosuppression‐related conditions. A rather elusive topic in the posttransplant setting remains the impact of the underlying disease process and donor lungs on other organ systems and the complications arising from the complex physiologic interactions. The liver represents a vital organ often impacted in many ways by the lung transplant procedure. Also, there is a higher likelihood of adverse outcomes in OLT recipients who have significant liver pathology. Yet little is known about the morphologic changes in liver after patients have received an OLT. In this study we retrospectively reviewed liver pathology cases obtained after the patient received an OLT.Methods and results: Histology was reviewed by three pathologists and evaluated with a standardized checklist format. In our cohort, we found morphologic features of hepatic injury in the form of vascular outflow obstruction, nodular regenerative hyperplasia, portal vessel changes, and steatosis/steatohepatitis, but there was a striking absence of advanced fibrosis in our cohort.Conclusion: Here we present the first comprehensive account of morphologic changes in livers of post‐OLT patients. We believe that this information will aid clinical decision‐making during monitoring of hepatic function and fibrosis in patients with OLT and other complex pulmonary diagnoses.


  • Open Access

    A Case of Immune Checkpoint Inhibitor–Induced Duodenitis

    by Sandra Au, Wei Chen, Iris Vance, Kara Wegermann

    Immune checkpoint inhibitors improve patient survival in multiple cancers, but immune-related adverse events, including new immunologic conditions arising during therapy, pose a significant challenge. Gastrointestinal immune-related adverse events, although common, exhibit diverse presentations. We present a case of duodenitis resembling celiac disease because of the anti–programmed cell death protein-1 antibody, pembrolizumab. Despite diagnostic uncertainty and therapeutic interventions, including gluten-free diet, symptoms stabilized even with resuming gluten. In addition, endoscopic abnormalities after pembrolizumab therapy have neither progressed nor completely resolved. This case underscores the need for investigation into the pathogenesis of immune checkpoint inhibitor–induced duodenitis, with implications for care of patients on immunotherapies.